Heart failure (HF) is a clinical syndrome characterized by impaired cardiac pumping function that fails to effectively deliver blood to various parts of the body to meet metabolic needs. In China, there are a large number of HF patients, and the prevalence rate of HF is on the rise against the backdrop of an aging population. Research data shows that in China, the number of HF patients over 25 years old was about 12.1 million in 2017, with approximately 3 million new HF patients each year. Based on the scale of the HF patient population of 12.1 million people, calculated at an average penetration rate of 3% and an average device price of 55,000 yuan, the domestic HF device market size reaches approximately 20 billion RMB. As major strategic products and innovative medical devices, HF devices are not only key industries under national development plans but also important medical products for improving treatment outcomes and ensuring people's life and health. With the rapid progress of the industry, the development and innovation of HF devices have received high attention from the government and all sectors of society. With increasing doctor recognition, accelerating social aging, and improving patient affordability and willingness, the future market prospects for the HF device industry are broad. For this reason, based on research into this market, Frost & Sullivan (Frost & Sullivan) has released the '2024 China HF Device White Paper'.
If you have further research needs on the Chinese HF device market, please contact us:
Mr. Zhou from Frost & Sullivan
Tel: (+86)155-0092-6377
E-mail: albus.zhou@frostchina.com
